2024-04-29 12:09:51 ET
Summary
- Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis.
- The company's iPSCs technology creates renewable off-the-shelf cell therapies for hematological malignancies and solid tumors.
- Fate Therapeutics has a healthy cash position and is expected to report positive data from clinical trials, potentially leading to exponential growth and significant market share.
...
Read the full article on Seeking Alpha
For further details see:
Fate Therapeutics: Looking For A Potential Turnaround In 2024